gdc

FDA Approvals, News & Updates

Trodelvy New Therapy Approved for Triple-Negative Breast Cancer
Breast CancerFDA Approvals, News & Updates
In April, 2020, the FDA approved Trodelvy for the treatment of adults with metastatic triple-negative breast cancer after 2 or more previous therapies.
Tabrecta Approved for NSCLC with MET Biomarker
BiomarkersFDA Approvals, News & Updates

On May 6, 2020, the FDA approved Tabrecta (capmatinib; from Novartis), an oral kinase inhibitor, for adults with metastatic (spreading) non–small-cell lung cancer (NSCLC).

Zejula Now Approved as First-Line Maintenance Therapy in All Patients with Ovarian Cancer
FDA Approvals, News & UpdatesOvarian Cancer
In April 2020, the FDA approved Zejula for long-term maintenance therapy for all patients with advanced ovarian cancer, regardless of any gene mutations.
Pemazyre First Therapy Approved for Cholangiocarcinoma with FGFR2 Biomarker
CholangiocarcinomaFDA Approvals, News & Updates
In April, the FDA approved Pemazyre, the first targeted drug for patients with advanced cholangiocarcinoma and a biomarker called FGFR2 gene fusion.
Tukysa Approved for Breast Cancer and HER2 Biomarker
Breast CancerFDA Approvals, News & Updates
Another drug approved by the FDA in April, Tukysa, a kinase inhibitor, is a new treatment option for the treatment of patients with advanced HER2-positive breast cancer.
Bladder CancerFDA Approvals, News & UpdatesUrothelial Cancer
In April 2020, the FDA approved Jelmyto as the first treatment for low-grade upper-tract urothelial cancer, a rare cancer that affects the urinary system.
FDA and CDC Investigate Outbreak of Vaping-Related Illness
FDA Approvals, News & UpdatesNewsworthyWeb Exclusives
In the past week, the US Food and Drug Administration (FDA) has released 2 public announcements related to the use of vaping products.
Polivy a New Targeted Immunotherapy Approved for Patients with B-Cell Lymphoma
FDA Approvals, News & UpdatesLymphomaNewsworthy
In June 2019, the FDA approved a new type of immunotherapy called Polivy, for use in combination with other drugs, in patients with previously treated diffuse large B-cell lymphoma (DLBCL), offering new options for patients whose cancer has returned.
Page 1 of 7
Results 1 - 10 of 65

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country